Cerewint is under clinical development by Regeneration Biomedical and currently in Phase I for Alzheimer’s Disease. According to GlobalData, Phase I drugs for Alzheimer’s Disease have a 63% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Cerewint’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Cerewint overview
Cerewint (RB-ADSC) is under development for the treatment of Alzheimer's disease (AD). The therapeutic candidate comprises of autologous adipose-derived stem cells (ADSCs). It is administered through intracerebroventricular route.
Regeneration Biomedical overview
Regeneration Biomedical leverages stem cell therapy development and clinical application with focus on Alzheimer’s Disease, ALS, multiple sclerosis, Parkinson’s disease and its variants, stroke, and traumatic brain injury (including chronic traumatic encephalopathy (CTE).
For a complete picture of Cerewint’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
